secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0001193125-25-221527
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zelicapavir shows 6.7-day symptom resolution improvement in high-risk RSV adults
--------------------------------------------------------------------------------

- 6.7-day faster complete resolution of all 13 RSV symptoms in HR3 population (COPD/CHF/age≥75); 7.2-day improvement in total RiiQ.
- Hospitalization rate 1.7% for zelicapavir vs 5.0% placebo; 2-day faster PGI-S improvement (p<0.05).
- Robust antiviral effect: 4–5 day faster undetectable viral load; 23.5% vs 10.0% undetectable at end of treatment (p=0.0198).
- Favorable safety: no treatment discontinuations; most common AEs diarrhea (3.3%) and asthma (2.5%).
- Primary endpoint (time to mild LRTD symptoms) not met; data inform Phase 3 design and registrational endpoints.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000119312525221527/0001193125-25-221527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000119312525221527/d16388d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-221527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer